老虎證券

BRIEF-EMA's CHMP Recommends Against Sanofi's Rezurock

Reuters
10/17
BRIEF-EMA's CHMP Recommends Against <a href="https://laohu8.com/S/GCVRZ">Sanofi</a>'s Rezurock

Oct 17 (Reuters) - EMA's CHMP:

  • EMA'S CHMP: ADOPTED POSITIVE OPINION FOR WAYRILZ FOR TREATMENT OF IMMUNE THROMBOCYTOPENIA IN ADULT PATIENTS WHO ARE REFRACTORY TO OTHER TREATMENTS

  • EMA'S CHMP: RECOMMENDED GRANTING A MARKETING AUTHORISATION FOR BRINSUPRI

  • EMA'S CHMP: RECOMMENDED NOT GRANTING MARKETING AUTHORISATION FOR REZUROCK FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE

  • EMA'S CHMP: WITHDRAWS INITIAL MARKETING APPLICATION FOR HYDROCORTISONE AGUETTANT

  • EMA'S CHMP: ADOPTED NEW SUBCUTANEOUS ROUTE OF ADMINISTRATION FOR SAPHNELO, AN ADD-ON TREATMENT IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

  • EMA'S CHMP: CONFIRMED ITS INITIAL RECOMMENDATION TO NOT CONSIDER DEUTETRABENAZINE

  • EMA'S CHMP: POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR BREYANZI

  • EMA'S CHMP: POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR TREMFYA

  • EMA'S CHMP: CONFIRMS INITIAL RECOMMENDATION TO NOT CONSIDER DEUTETRABENAZINE AS NEW ACTIVE SUBSTANCE

  • EMA'S CHMP: POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR PAXLOVID

((Reuters.Briefs@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10